Safety concerns include cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and GvHD; IL-6 is a central CRS mediator and target of tocilizumab. Here, IL6 is linked to congenital rubella syndrome.